Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer

Recent developments and future perspectives in the systemic treatment of metastatic colorectal... Systemic treatment of metastatic colorectal cancer is increasingly being tailored towards the individual clinical situation of the patient. In particular, the k-ras mutation status as a predictive marker for the therapeutic efficacy of epidermal growth factor receptor (EGFR)-antibodies is now routinely implemented in clinical practice to define the subgroup of patients benefiting most from treatment. This review discusses the current status of treatment strategies using intermittent and maintenance therapy concepts based on recent clinical trials. Furthermore, the conflicting data on the use of the monoclonal EGFR-antibody cetuximab in combination with oxaliplatin containing chemotherapy derived from recent phase III trials are summarised and discussed. Finally, first clinical data on the use of monoclonal antibodies against novel targets (i.e. Hepatocyte Growth Factor and Insulin-like Growth Factor-1 Receptor) are presented. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/recent-developments-and-future-perspectives-in-the-systemic-treatment-2e4t0lR93T
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0265-4
Publisher site
See Article on Publisher Site

Abstract

Systemic treatment of metastatic colorectal cancer is increasingly being tailored towards the individual clinical situation of the patient. In particular, the k-ras mutation status as a predictive marker for the therapeutic efficacy of epidermal growth factor receptor (EGFR)-antibodies is now routinely implemented in clinical practice to define the subgroup of patients benefiting most from treatment. This review discusses the current status of treatment strategies using intermittent and maintenance therapy concepts based on recent clinical trials. Furthermore, the conflicting data on the use of the monoclonal EGFR-antibody cetuximab in combination with oxaliplatin containing chemotherapy derived from recent phase III trials are summarised and discussed. Finally, first clinical data on the use of monoclonal antibodies against novel targets (i.e. Hepatocyte Growth Factor and Insulin-like Growth Factor-1 Receptor) are presented.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 30, 2011

References

  • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
    Tournigand, C; Andre, T; Achille, E; Lledo, G; Flesh, M; Mery-Mignard, D; Quinaux, E; Couteau, C; Buyse, M; Ganem, G
  • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200
    Giantonio, BJ; Catalano, PJ; Meropol, NJ; O'Dwyer, PJ; Mitchell, EP; Alberts, SR; Schwartz, MA; Benson, AB
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H; Fehrenbacher, L; Novotny, W; Cartwright, T; Hainsworth, J; Heim, W; Berlin, J; Baron, A; Griffing, S; Holmgren, E
  • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Saltz, LB; Clarke, S; Diaz-Rubio, E; Scheithauer, W; Figer, A; Wong, R; Koski, S; Lichinitser, M; Yang, TS; Rivera, F
  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D; Humblet, Y; Siena, S; Khayat, D; Bleiberg, H; Santoro, A; Bets, D; Mueser, M; Harstrick, A; Verslype, C
  • Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with Chemotherapy-refractory metastatic colorectal cancer
    Van Cutsem, E; Peeters, M; Siena, S; Humblet, Y; Hendlisz, A; Neyns, B; Canon, JL; Van Laethem, JL; Maurel, J; Richardson, G
  • Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
    Douillard, JY; Siena, S; Cassidy, J; Tabernero, J; Burkes, R; Barugel, M; Humblet, Y; Bodoky, G; Cunningham, D; Jassem, J
  • Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
    Peeters, M; Price, TJ; Cervantes, A; Sobrero, AF; Ducreux, M; Hotko, Y; Andre, T; Chan, E; Lordick, F; Punt, CJ
  • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Van Cutsem, E; Kohne, CH; Hitre, E; Zaluski, J; Chang Chien, CR; Makhson, A; D'Haens, G; Pinter, T; Lim, R; Bodoky, G
  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado, RG; Wolf, M; Peeters, M; Van Cutsem, E; Siena, S; Freeman, DJ; Juan, T; Sikorski, R; Suggs, S; Radinsky, R
  • OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study
    Tournigand, C; Cervantes, A; Figer, A; Lledo, G; Flesch, M; Buyse, M; Mineur, L; Carola, E; Etienne, PL; Rivera, F
  • Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial
    Grothey, A; Hart, LL; Rowland, KM; Ansari, RH; Alberts, SR; Chowhan, NM; Shpilsky, A; Hochster, HS
  • Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD])
    Tabernero, J; Aranda, E; Gomez, A; Massuti, B; Sastre, J; Abad, A; Valladares, M; Rivera, F; Safont, M; Diaz-Rubio, E
  • Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Bokemeyer, C; Bondarenko, I; Makhson, A; Hartmann, JT; Aparicio, J; de Braud, F; Donea, S; Ludwig, H; Schuch, G; Stroh, C
  • Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
    Folprecht, G; Gruenberger, T; Bechstein, WO; Raab, HR; Lordick, F; Hartmann, JT; Lang, H; Frilling, A; Stoehlmacher, J; Weitz, J
  • Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104–A randomized trial of the German AIO CRC Study Group
    Moosmann, N; von Weikersthal, LF; Vehling-Kaiser, U; Stauch, M; Hass, HG; Dietzfelbinger, H; Oruzio, D; Klein, S; Zellmann, K; Decker, T
  • Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    Ocvirk, J
  • Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial
    Maughan, TS; Adams, R; Smith, CG; Seymour, MT; Wilson, RH; Meade, AM; Fisher, D; Madi, A; Cheadle, J; Kaplan, RS
  • Synergistic activity of the src family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress
    Kopetz, S; Lesslie, DP; Dallas, NA; Park, SI; Johnson, M; Parikh, NU; Kim, MP; Abbruzzese, JL; Ellis, LM; Chandra, J
  • Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study
    Kozloff, M; Yood, MU; Berlin, J; Flynn, PJ; Kabbinavar, FF; Purdie, DM; Ashby, MA; Dong, W; Sugrue, MM; Grothey, A
  • Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
    Van Cutsem, E; Rivera, F; Berry, S; Kretzschmar, A; Michael, M; DiBartolomeo, M; Mazier, MA; Canon, JL; Georgoulias, V; Peeters, M
  • The biological role of HGF-MET axis in tumor growth and development of metastasis
    Lesko, E; Majka, M
  • The EGF receptor interacts with the type 1 IGF receptor and regulates its stability
    Riedemann, J; Takiguchi, M; Sohail, M; Macaulay, V